Abstract
Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) induces apoptosis in immune cells bearing the RCAS1 receptor. We sought to determine RCAS1 involvement in the origin and progression of gallbladder cancer, and also implications of RCAS1 for patient survival. RCAS1 expression was examined immunohistochemically in 110 surgically resected gallbladder specimens. The gallbladders represented 20 cases of cholecystitis with no associated pancreaticobiliary maljunction; 23 cases of cholecystitis with pancreaticobiliary maljunction; 14 cases of adenomyomatosis; 7 adenomas; and 46 cancers. High expression of RCAS1 (immunoreactivity in over 25% of cells) was observed in 32 of the 46 cancers (70%), but not in other diseases, including pre-cancerous conditions. RCAS1 immunoreactivity was associated with depth of tumour invasion (P = 0.0180), lymph node metastasis (P = 0.0033), lymphatic involvement (P = 0.0104), venous involvement (P = 0.0224), perineural involvement (P = 0.0351) and stage by the tumour, nodes and metastases (TNM) classification (P = 0.0026). Thus, RCAS1 expression may be a relatively late event in gallbladder carcinogenesis possibly promoting tumour progression. Cox regression multivariate analysis demonstrated RCAS1 positivity to be an independent negative predictor for survival (P = 0.0337; risk ratio, 12.690; 95% confidence interval, 1.216–132.423). High expression of RCAS1 significantly correlated with tumour progression and predicted poor outcome in gallbladder cancer. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ajiki T, Fujimori T, Onoyama H, Yamamoto M, Kitazawa S, Maeda S and Saitoh Y (1996a) K-ras gene mutation in gall bladder carcinomas and dysplasia. Gut 38: 426–429
Ajiki T, Onoyama H, Yamamoto M, Asaka K, Fujimori T, Maeda S and Saitoh Y (1996b) p53 protein expression and prognosis in gall bladder carcinoma and premalignant lesions. Hepatogastroenterology 43: 521–526
Anayama T, Furihara M, Ishikawa T, Ohtsuki Y and Ogoshi S (1998) Positive correlation between p27Kipl expression and progression of human esophageal squamous cell carcinoma. Int J Cancer 79: 439–443
Aoki H, Sugatani H and Shimazu M (1987) A clinical study on cancer of the bile duct associated with anomalous arrangement of pancreaticobiliary ductal system: analysis of 569 cases collected in Japan. J Biliary Tract Pancreas 8: 1539–1551
Bartlett DL, Fong Y, Fortner JG, Brennan MF and Blumgart LH (1996) Long-term results after resection for gallbladder cancer: implications for staging and management. Review. Ann Surg 224: 639–646
Benoist S, Panis Y and Fagniez PL (1998) Long-term results after curative resection for carcinoma of the gallbladder: French University Association for Surgical Research. Am J Surg 175: 118–122
Casey JL, Pedley RB, King DJ, Green AJ, Yarranton GT and Begent RH (1999) Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab’ fragments. Br J Cancer 81: 972–980
Iwasaki T, Nakashima M, Watanabe T, Yamamoto S, Inoue Y, Yamanaka H, Matsumura A, Aluchi K, Mori T and Okada M (2000) Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1. Int J Cancer 89: 488–493
Kaku T, Sonoda K, Kamura T, Hirakawa T, Sakai K, Amada S, Ogawa S, Kobayashi H, Nakashima M, Watanabe T and Nakano H (1999) The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix. Clin Cancer Res 5: 1449–1453
Katoh T, Nakai T, Hayashi S and Satake T (1988) Noninvasive carcinoma of the gallbladder arising in localized type adenomyomatosis. Am J Gastroenterol 83: 670–674
Kozuka S, Tsubone M, Yasui A and Hachisuka K (1982) Relation of adenoma to carcinoma in the gallbladder. Cancer 50: 2226–2234
Linden O, Tennvall J, Cavallin-Stahl E, Darte L, Garkavij M, Lindner KJ, Ljungberg M, Ohlsson T, Sjogreen K, Wingardh K and Strand SE (1999) Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. Clin Cancer Res 5: 3287s–3291s
Loda M, Cukor B, Tam SW, Lavin P, Piorentino M, Draetta GF, Jessup JM and Pagano M (1997) Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3: 231–234
Nakashima M, Sonoda K and Watanabe T (1999) Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 5: 938–942
Ogura Y, Mizumoto R, Isaji S, Kusuda T, Matsuda S and Tabata M (1991) Radical operations for carcinoma of the gallbladder: present status in Japan. World J Surg 15: 337–343
Ootani T, Shirai Y, Tsukada K and Muto T (1992) Relationship between gallbladder carcinoma and the segmental type of adenomyomatosis of the gallbladder. Cancer 69: 2647–2653
Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR and Roberts JM (1997) Expression of cell-cycle regulators p27Kipl and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222–225
Shimada H, Endo I, Togo S, Nakano A, Izumi T and Nakagawara G (1997) The role of lymph node dissection in the treatment of gallbladder carcinoma. Cancer 79: 892–899
Sobin LH and Wittekind CH (1997) TNM classification of malignant tumours. 5th edn, Wiley-Liss: New York
Sonoda K, Nakashima M, Saito T, Amada S, Kamura T, Nakano H and Watanabe T (1995) Establishment of a new human uterine cervical adenocarcinoma cell line, SiSo, and its reactivity to anticancer reagents. Int J Oncol 6: 1099–1194
Sonoda K, Nakashima M, Kaku T, Kamura T, Nakano H and Watanabe T (1996) A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer 77: 1501–1509
Uchimura M, Waki S, Kida E, Kanda K, Narita K, Maeda S, Soejima H, Okamoto K and Ozawa A (1991) Anomalous arrangement of pancreaticobiliary ductal system and biliary carcinoma. J Biliary Tract Pancreas 12: 397–404
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Oshikiri, T., Hida, Y., Miyamoto, M. et al. RCAS1 as a tumour progression marker: an independent negative prognostic factor in gallbladder cancer. Br J Cancer 85, 1922–1927 (2001). https://doi.org/10.1054/bjoc.2001.2192
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2192
Keywords
This article is cited by
-
The Involvement of RCAS1 in Creating a Suppressive Tumor Microenvironment in Patients with Salivary Gland Adenocarcinoma
Cancer Microenvironment (2011)
-
Accuracy of differential diagnosis for pancreatic cancer is improved in the combination of RCAS1 and CEA measurements and cytology in pancreatic juice
Medical Molecular Morphology (2011)
-
The association between RCAS1 expression in laryngeal and pharyngeal cancer and its healthy stroma with cancer relapse
BMC Cancer (2009)
-
Cancer therapy using tumor-associated antigens to reduce side effects
Clinical and Experimental Medicine (2009)
-
Clinical Significance of Tumor-associated Antigen RCAS1 Expression in Human Pancreatic Ductal Adenocarcinoma
Digestive Diseases and Sciences (2008)